Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

Trial Identifier: D5290C00006
Sponsor: AstraZeneca
Collaborator:
IQVIA RDS Inc.
Start Date: November 2021
Primary Completion Date: November 2025
Study Completion Date: November 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100191
CN Changde, CN, 415003
CN changsha, CN, 410005
CN Changsha, CN, 410008
CN Chengdu, CN, 610041
CN Chengdu, CN, 610000
CN Guangzhou, CN, 510150
CN Guangzhou, CN, 510120
CN Guangzhou, CN, 510280
CN hangzhou, CN, 310006
CN Hangzhou, CN, 310013
CN Jiaxing, CN, 314000
CN Kunming, CN, 650101
CN Langfang, CN
CN Linfen, CN, 041099
CN Linfen, CN, 41081
CN Nanjing, CN, 210009
CN Ningbo, CN, 315012
CN Sanmenxia, CN, 472000
CN Sanya City, CN, 572000
CN Shantou, CN, 515041
CN Shaoxing, CN, 311800
CN Shenzhen, CN, 518106
CN Suzhou, CN, 215002
CN Tangshan, CN, 63003
CN Tianjin, CN, 300074
CN Tianjin, CN, 300201
CN Tonghua, CN, 134000
CN Wenzhou, CN, 325027
CN Wuxi, CN, 214023
CN Xinxiang, CN, 453000
CN Zhengzhou, CN, 450018
CN Zhongshan, CN, 528400